{"schema_version":"secwatch.filing_event.v1","accession":"0000320017-23-000021","form_type":"8-K","ticker":"LSTA","cik":"0000320017","company_name":"LISATA THERAPEUTICS, INC.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:41.786303+00:00","generated_at":"2026-06-16T05:30:39.396022+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lisata Therapeutics eliminates President & CBO role, terminates David Slack effective May 1, 2023","bullets":["Position of President and Chief Business Officer eliminated; David Slack terminated immediately.","Slack resigned from Board of Directors per employment agreement.","Severance: $478,400 over 12 months; bonus of $239,200 (50% of base salary) paid over same period.","Additional lump sum of $24,134 for earned pay, PTO, and expenses; COBRA assistance provided.","Vested option exercise period extended to three years post-termination or remaining term, whichever shorter."],"urls":{"canonical":"https://secwatch.observer/filing/0000320017-23-000021","json":"https://secwatch.observer/filing/0000320017-23-000021.json","markdown":"https://secwatch.observer/filing/0000320017-23-000021.md","text":"https://secwatch.observer/filing/0000320017-23-000021.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/0000320017-23-000021-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/clbs-20230501.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:30:39.396022+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"bd949c2a7b","claim":"David Slack was terminated as President and Chief Business Officer at LISATA THERAPEUTICS, INC..","evidence_excerpt":"On May 1, 2023, Lisata Therapeutics, Inc. (the “Company”), after a careful review of capital utilization and prioritization, eliminated the position of President and Chief Business Officer, and terminated the employment of Mr. David Slack, effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/0000320017-23-000021-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated"},{"label":"Role","value":"President and Chief Business Officer"}],"fact_type":"executive_change"},{"claim_id":"c8722d7292","claim":"David Slack resigned as Director at LISATA THERAPEUTICS, INC..","evidence_excerpt":"Mr. Slack has effectively resigned from the Company’s Board of Directors as of May 1, 2023 pursuant to the terms of his Employment Agreement.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/320017/000032001723000021/0000320017-23-000021-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}